JP2012505891A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505891A5
JP2012505891A5 JP2011532175A JP2011532175A JP2012505891A5 JP 2012505891 A5 JP2012505891 A5 JP 2012505891A5 JP 2011532175 A JP2011532175 A JP 2011532175A JP 2011532175 A JP2011532175 A JP 2011532175A JP 2012505891 A5 JP2012505891 A5 JP 2012505891A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
halogen
pyridinyl
alkoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532175A
Other languages
English (en)
Japanese (ja)
Other versions
JP5529876B2 (ja
JP2012505891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060436 external-priority patent/WO2010045188A1/en
Publication of JP2012505891A publication Critical patent/JP2012505891A/ja
Publication of JP2012505891A5 publication Critical patent/JP2012505891A5/ja
Application granted granted Critical
Publication of JP5529876B2 publication Critical patent/JP5529876B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532175A 2008-10-17 2009-10-13 Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物 Expired - Fee Related JP5529876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10620708P 2008-10-17 2008-10-17
US61/106,207 2008-10-17
PCT/US2009/060436 WO2010045188A1 (en) 2008-10-17 2009-10-13 Heteroaryl substituted indole compounds useful as mmp-13 inhibitors

Publications (3)

Publication Number Publication Date
JP2012505891A JP2012505891A (ja) 2012-03-08
JP2012505891A5 true JP2012505891A5 (enExample) 2012-11-29
JP5529876B2 JP5529876B2 (ja) 2014-06-25

Family

ID=41508906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532175A Expired - Fee Related JP5529876B2 (ja) 2008-10-17 2009-10-13 Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物

Country Status (5)

Country Link
US (1) US8785489B2 (enExample)
EP (1) EP2340243B1 (enExample)
JP (1) JP5529876B2 (enExample)
CA (1) CA2738929A1 (enExample)
WO (1) WO2010045188A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045190A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
US8637550B2 (en) 2008-11-17 2014-01-28 Boehringer Ingelheim International Gmbh Heteroaryl diamide compounds useful as MMP-13 inhibitors
BR112012006630A2 (pt) * 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
US10730866B2 (en) * 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017165139A1 (en) 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (zh) 2016-07-30 2022-04-19 百时美施贵宝公司 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
JP7652772B2 (ja) * 2019-11-01 2025-03-27 ブリストル－マイヤーズ スクイブ カンパニー 置換ピラゾール化合物
EP4200297B1 (en) 2020-08-19 2026-05-13 Bristol-Myers Squibb Company Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
US12492188B2 (en) 2020-08-19 2025-12-09 Bristol-Myers Squibb Company 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis
WO2022040267A1 (en) 2020-08-19 2022-02-24 Bristol-Myers Squibb Company 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
CN116947821B (zh) * 2022-04-20 2025-10-17 成都肯迪特生物医药科技有限公司 一种化合物及其在制备jak激酶抑制剂中的用途
US20260092058A1 (en) 2024-09-30 2026-04-02 St. Jude Children's Research Hospital, Inc. Small Molecule Degraders and Fluorescent Probes of PXR

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151380A (ja) * 1994-11-29 1996-06-11 Kyorin Pharmaceut Co Ltd ビス（トリフルオロメチルピロロインドールカルボン酸エステル）誘導体及びその製造方法
AU2164300A (en) 1998-12-04 2000-06-26 N.V. Organon Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
HUP0302966A2 (hu) 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB0018758D0 (en) 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
WO2003020699A2 (en) * 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003234464B2 (en) * 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
EP1636224B1 (en) 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase
KR20060079190A (ko) 2003-08-14 2006-07-05 아사히 가세이 파마 가부시키가이샤 치환 아릴알칸산 유도체 및 그의 용도
US20080275028A1 (en) 2004-07-20 2008-11-06 Giovanni Gaviraghi Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof
EP1820795A4 (en) * 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
EP1838690A2 (en) 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
EP1860098B1 (en) * 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
MX2008001778A (es) 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2010045190A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
EP2340243B1 (en) 2008-10-17 2014-10-08 Boehringer Ingelheim International GmbH Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
US8637550B2 (en) 2008-11-17 2014-01-28 Boehringer Ingelheim International Gmbh Heteroaryl diamide compounds useful as MMP-13 inhibitors

Similar Documents

Publication Publication Date Title
JP2010031025A5 (enExample)
CN101784532B (zh) Hiv逆转录酶抑制剂
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
CN110582489A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2013518110A5 (enExample)
JP2013505969A5 (enExample)
JP2009530283A5 (enExample)
JP2010510231A5 (enExample)
JP2013544854A5 (enExample)
JP2012507566A5 (enExample)
JP2017214387A5 (enExample)
CA2451981A1 (en) 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
JP2008535903A5 (enExample)
JP2012530137A5 (enExample)
JP2016190843A5 (enExample)
JP2007524696A5 (enExample)
JP2016196492A5 (enExample)
JP2013540712A5 (enExample)
JP2011513305A5 (enExample)
JP2015051994A5 (enExample)
RU2008140943A (ru) Аналоги тиазолидиндиона
JP2017508795A5 (enExample)
RU2015147447A (ru) Производные доластатина 10 и ауристатинов
US8093245B2 (en) 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use
RU2012136624A (ru) Фармацевтические композиции для лечения боли и других показаний